Zelira Therapeutics Limited (ZLDAF)
Zelira Therapeutics Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Perth, WA, AU. The stock last traded at $0.26, up 0.00% on the session, giving a market capitalisation of $3.4M. On trailing twelve-month figures it carries a trailing P/E of -1.56, a net margin of -553029.3%. Its beta of 0.59 implies it has historically moved less than the broad market.
Zelira Therapeutics Limited is an Australian biopharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-derived therapeutic agents, aimed at treating a variety of medical conditions. The firm offers its HOPE brand formulations in Pennsylvania and Louisiana, and is actively developing Zenivol, a cannabinoid-based medicine specifically designed for chronic insomnia. Beyond its prescription products, Zelira also markets several over-the-counter (OTC) items, including SprinJene for oral care and RAF FIVE for dermatological applications. A notable OTC offering is ITURA, an advanced topical cream formulated to alleviate multiple symptoms such as numbness, tingling sensations, muscle cramps, reduced sensitivity, and pain frequently associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has cultivated strategic partnerships with prominent institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Incorporated in 2003, the company, which officially changed its name from Zelda Therapeutics Limited in December 2019, maintains its corporate headquarters in Perth, Australia.
Zelira Therapeutics Limited is most often compared with the following Healthcare names: